This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2015 by Natavudh Townamchai, MD, Chulalongkorn University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Natavudh Townamchai, MD, Chulalongkorn University Identifier:
First received: December 25, 2012
Last updated: February 1, 2015
Last verified: February 2015
Study safety of longterm immunosuppressive protocol with Sirolimus plus Prednisolone, and Calcineurin inhibitor withdrawal.

Condition Intervention Phase
Renal Transplant Other: Withdraw cyclosporine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Natavudh Townamchai, MD, Chulalongkorn University:

Primary Outcome Measures:
  • longterm glomerular filtration rate defined by eGFR CKD-EPI [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Acute rejection rate [ Time Frame: 5 years ]

Estimated Enrollment: 30
Study Start Date: August 2010
Estimated Study Completion Date: October 2015
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sirolimus with Prednisolone
Sirolimus with Prednisolone, and withdraw cyclosporine
Other: Withdraw cyclosporine
No Intervention: Sirolimus with Cyclosporine with Prednisolone

Detailed Description:

Sirolimus with Cyclosporine minimization is the standard protocol for kidney transplantation in Chulalongkorn University. The investigators published the safety of this regimen in Transplantation Proceeding 2008; 40: 2206-8.

The investigators now further study in those patients who doing well with this regimen more than 1 year. The patients will be asked for kidney biopsy to evaluate and make sure they don't have subclinical rejection. The patients who don't have subclinical rejection will discontinue cyclosporine and continue with only sirolimus and prednisolone.


Ages Eligible for Study:   15 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Kidney transplant with Sirolimus plus Cyclosporine plus Prednisolone more than 1 year

Exclusion Criteria:

  • history of acute rejection, or subclinical rejection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01758107

Contact: Natavudh Townamchai, MD +66894904222

Chulalongkorn University Recruiting
Bangkok, Thailand
Contact: Natavudh Townamchai, MD    +66894904222   
Principal Investigator: Natavudh Townamchai, MD         
Sponsors and Collaborators
Chulalongkorn University
  More Information

Responsible Party: Natavudh Townamchai, MD, MD, Chulalongkorn University Identifier: NCT01758107     History of Changes
Other Study ID Numbers: monorapa
Study First Received: December 25, 2012
Last Updated: February 1, 2015

Additional relevant MeSH terms:
Methylprednisolone Hemisuccinate
Prednisolone acetate
Methylprednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Anti-Bacterial Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antiemetics processed this record on September 19, 2017